About Unimark Remedies Limited
Data last updated:
Unimark Remedies Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 01 December 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U23200MH1993PLC075373. Its GSTIN is 27AAACU0589R1ZL (Maharashtra). The company holds 9 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹57.01 Cr and a paid-up capital of ₹10 Cr. It was formerly known as Unimark Remedies Private Limited. It is led by directors including Jitesh Khokhani Rameshchandra and Sonalika Sushant Shrivastav.
Its last annual general meeting (AGM) was held on 29 December 2018, and its latest financial statements are for the year ended 31 March 2018. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2019, the company reported a revenue of ₹104.12 Cr, a decline of 30% compared to the previous year. For the same year it recorded a net loss of ₹197.07 Cr (net margin -189.3%) and EBITDA of -₹42.05 Cr (EBITDA margin -40.4%). Revenue has declined at a compounded annual rate (CAGR) of 26% over three years.
The company has about 4 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Unimark remedies. As per MCA filings, the company has open charges of ₹1,105.65 Cr and satisfied charges of ₹344.73 Cr on record. Court records list 211 cases involving the company, including 63 filed by the company and 149 filed against it; 29 cases are pending. The company has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹379.05 Cr; the latest was in March 2025. Its 8 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Allchem Lifescience Limited with revenue of ₹152.78 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website unimarkremedies.com.
Company details
CIN history
Unimark Remedies has one previous CIN (Corporate Identification Number): U23200MH1993PTC075373. The current CIN is U23200MH1993PLC075373, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U23200MH1993PLC075373 | Current |
| U23200MH1993PTC075373 | Previous |
Contact details
Unimark Remedies Limited's registered office is in Mumbai, Maharashtra. Its website is unimarkremedies.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot – 83C Ground Floor Motor Cycle Building Laxminarsingh, Papan Marg Off. Dr. E Moses Road Gandhi Nagar Worli, Mumbai, Maharashtra, India – 400018
- IndustryPharma, API Manufacturers
To see the full contact details of Unimark Remedies Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Unimark Remedies operates one associated brand: Unimark remedies. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Traditional vertically integrated pharmaceutical company having presence in various business segments | unimarkremedies.com |
Business activity
The main business activity of Unimark Remedies is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Unimark Remedies Limited, buy the company report.
Financials of Unimark Remedies Limited
FY 2018 filings availableUnimark Remedies Limited reported revenue of ₹104.12 Cr (down 30% YoY) for FY 2019.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 26% over three years, including a 30% fall in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹104.12 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹42.05 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹197.07 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -40.4% | ||||
| Net Profit Margin | -189.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Unimark Remedies Limited, buy the company report.
Board of directors and KMP of Unimark Remedies Limited
Unimark Remedies Limited currently reports 3 directors and 1 key managerial person. 29 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sonalika Sushant Shrivastav Also directs: Shamrock Industrial Company Limited | Additional Director | 06 Sep 2024 | 2 Years 1 Months | Current |
| Jitesh Khokhani Rameshchandra | Director | 26 May 2023 | 3 Years 5 Months | Current |
| Ketan Bhupendrabhai Parikh | Additional Director | 27 May 2023 | 3 Years 5 Months | Current |
| Kamlesh Rameshchandra Khokhani Also directs: Guideline Property Solutions LLP, Raajshi Invecorp LLP, Shamrock Steriotech LLP and 5 more | Cfo | 06 Sep 2024 | 2 Years 1 Months | Current |
Peer comparison
Unimark Remedies Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Allchem Lifescience Limited | ₹152.78 Cr (FY 2025) | 11.0% | Vadodara, Gujarat, India | |||
| Rampex Labs Private Limited | ₹152.68 Cr (FY 2025) | 16.0% | Bollaram Villege, Telangana, India | |||
| SPC Life Sciences Limited | ₹151.89 Cr (FY 2025) | -3.0% | Vadodara, Gujarat, India | |||
| Therapiva Private Limited | ₹148.94 Cr (FY 2021) | -23.0% | Secunderabad, Telangana, India | |||
| Atlas Life Sciences Private Limited | ₹148.18 Cr (FY 2022) | 35.0% | Ahmedabad, Gujarat, India | |||
| Sionc Pharmaceuticals Private Limited | ₹147.51 Cr (FY 2024) | 13.0% | Visakhapatnam, Andhra Pradesh, India | |||
| Jay Finechem Private Limited | ₹145.44 Cr (FY 2025) | 187.0% | Mumbai, Maharashtra, India | |||
| Lyka Labs Limited | ₹140.73 Cr (FY 2025) | 25.0% | Ankleshwar, Gujarat, India | |||
| Unimark Remedies Limitedthis company | ₹104.12 Cr (FY 2019) | -₹197.07 Cr | -189.3% | -30.0% | 4 | Mumbai, Maharashtra, India |
To see the full peer comparison of Unimark Remedies Limited, buy the company report.
Auditor
Unimark Remedies Limited is audited by Dhiraj & Dheeraj for the financial year 2019.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Dhiraj & Dheeraj | FY 2019 | 0102454W |
Shareholding
The shareholding of Unimark Remedies Limited is on record for 3 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Unimark Remedies Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 02 Sep 2025 | 101158384 | Others | ₹35 Cr | Open | |
| 30 Jul 2024 | 100973450 | Others | ₹50 Cr | Open | |
| 03 Jun 2014 | 10504410 | Idbi Trusteeship Services Limited | ₹913.75 Cr | Open | |
| 06 Mar 2013 | 10415825 | Others | ₹1.8 Cr | Open | |
| 06 Mar 2013 | 10415530 | Others | ₹49.04 Lakh | Open |
To see the full charge records of Unimark Remedies Limited, buy the company report.
Total charge records: 59 View all charges
Deals & funding
Unimark Remedies Limited has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹379.05 Cr; the latest was in March 2025.
Deals on record (5 of 12)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Debt financing | ₹20 Cr | Investors: Icici Bank Limited , Export Import Bank of India, Omkara Assets Reconstruction Private Limited |
| Mar 2017 | Secondary share transfer | Undisclosed | Buyer: Mehul Jayant Parekh HUF, Swiss Venture Capital Private Limited, an individual Seller: Jayant Mohanlal Parekh HUF, EQ India Advisors, an individual |
| Jun 2016 | Funding round | ₹77.07 Cr | Investors: Icici Bank Limited , Export Import Bank of India, CENTRAL BANK OF INDIA |
| Mar 2016 | Secondary share transfer | Undisclosed | Buyer: Royal Star Limited Seller: Hikma Pharmaceuticals LLC |
| Mar 2006 | Funding round | ₹2.03 Cr | Investors: 4 individuals |
To see the full deal history of Unimark Remedies Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Unimark Remedies Limited has 211 court cases on record: 63 filed by Unimark Remedies, 149 filed against it. 29 cases are pending and 182 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 132 | 91 | 21 |
| High courts | 57 | 36 | 4 |
| NCLAT | 13 | 13 | 3 |
| NCLT | 5 | 5 | 0 |
| Supreme Court | 4 | 4 | 1 |
Cases on record (5 of 211)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Ahmedabad, Gujarat | Criminal complaint | Filed against the company by Dasaldhan Chemicals Pvt Ltd. | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Unimark Remedies Ltd | Pending |
| High Court, MAHARASHTRA | Court case (OLR) | Filed against the company by Official Liquidator of KDL Biotech Ltd. (in Liquidation) | Pending |
| Bombay High Court | Interim or miscellaneous application | Filed by the company against Unimark Remedies Limited and 4 others | Pending |
| NCLAT, Interlocutory Application | Interim or miscellaneous application | Filed against the company by Shamrock Pharmachemi Pvt Ltd | Disposed |
To see the full case history of Unimark Remedies Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Unimark Remedies Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Group structure & subsidiaries
Unimark Remedies has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2018. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Onkology Kombine Private Limited | U24100MH2009PTC194712 | |
| Zen Life Sciences Private Limited | U85190MH2008PTC188384 |
To see the full group structure of Unimark Remedies Limited, buy the company report.
Employees & EPFO
Unimark Remedies Limited has a workforce of 4 employees on its EPFO records as of Apr 07, 2024, across 3 active EPFO establishments.
GST
Unimark Remedies has 9 GST registrations: 3 active and 6 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACU0589R1ZL | Maharashtra | Active | 01 Jul 2017 |
| 02AAACU0589R1ZX | Himachal Pradesh | Active | 01 Jul 2017 |
| 24AAACU0589R1ZR | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Unimark Remedies Limited, buy the company report.
Recent activity
Unimark Remedies Limited has 32 board changes on record since 2008: 4 appointments and 28 cessations. The latest: Kamlesh Rameshchandra Khokhani was appointed as CFO on 06 Sep 2024.
151 earlier events are in the company report.
Frequently asked questions
Unimark Remedies is an active public limited company based in Mumbai, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 01 December 1993 (33+ years old) and is registered under CIN U23200MH1993PLC075373.
Unimark Remedies has 4 current directors and KMP:
- Sonalika Sushant Shrivastav - Additional Director
- Jitesh Khokhani Rameshchandra - Director
- Ketan Bhupendrabhai Parikh - Additional Director
- Kamlesh Rameshchandra Khokhani - Cfo
The latest financial statements of Unimark Remedies on record with the MCA are for the year ended 31 March 2018. Its last annual general meeting was held on 29 December 2018. Year-wise statements from 2015 are in the company report.
The GSTIN of Unimark Remedies is 27AAACU0589R1ZL, registered in Maharashtra. The company has 9 GST registrations in all, of which 3 are active and 6 are cancelled or inactive. Other active GSTINs include 02AAACU0589R1ZX (Himachal Pradesh), 24AAACU0589R1ZR (Gujarat).
The CIN (Corporate Identification Number) of Unimark Remedies is U23200MH1993PLC075373. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Unimark Remedies has 211 court cases on record: 63 filed by the company and 149 filed against it. 29 are pending. Most are in the district courts.
Unimark Remedies was incorporated on 01 December 1993, making it 33+ years old. It is registered with the Registrar of Companies, Mumbai.
Unimark Remedies has 12 deals on record (6 secondary share transfers, 4 funding rounds, 1 convertible or debt financing), with disclosed funding of ₹379.05 Cr; the latest was in March 2025.
The peers of Unimark Remedies by revenue are Allchem Lifescience Limited, Rampex Labs Private Limited, SPC Life Sciences Limited, Therapiva Private Limited, Atlas Life Sciences Private Limited and 3 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Kamlesh Rameshchandra Khokhani was appointed as CFO on 06 Sep 2024. Sonalika Sushant Shrivastav was appointed as Additional Director on 06 Sep 2024. Kamlesh Rameshchandra Khokhani ceased to be Director on 05 Sep 2024. Unimark Remedies has 32 board changes on record in total.
Unimark Remedies can be reached through the website unimarkremedies.com. Its registered office is in Mumbai, Maharashtra, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
